IDEAYA Biosciences
11
7
11
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
9%
1 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Role: lead
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Role: lead
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Role: lead
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Role: lead
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Role: lead
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Role: lead
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Role: lead
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Role: lead
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Role: collaborator
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Role: lead
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Role: lead
All 11 trials loaded